These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21638937)

  • 1. Gene expression profiling in women with lymph-node-positive breast cancer to select adjuvant chemotherapy treatment.
    Technol Eval Cent Assess Program Exec Summ; 2010 Nov; 25(1):1-4. PubMed ID: 21638937
    [No Abstract]   [Full Text] [Related]  

  • 2. Gene expression profiling in women with lymph node-negative breast cancer to select adjuvant chemotherapy.
    Blue Cross Blue Shield Asssociation
    Technol Eval Cent Assess Program Exec Summ; 2014 Oct; 29(3):1-10. PubMed ID: 25577824
    [No Abstract]   [Full Text] [Related]  

  • 3. Gene expression profiling of breast cancer to select women for adjuvant chemotherapy.
    Technol Eval Cent Assess Program Exec Summ; 2008 Apr; 22(13):1-8. PubMed ID: 18663816
    [No Abstract]   [Full Text] [Related]  

  • 4. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
    Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L
    Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
    Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making.
    Chao C; Studts JL; Abell T; Hadley T; Roetzer L; Dineen S; Lorenz D; YoussefAgha A; McMasters KM
    J Clin Oncol; 2003 Dec; 21(23):4299-305. PubMed ID: 14581440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling for managing breast cancer treatment.
    Technol Eval Cent Assess Program Exec Summ; 2005 May; 20(3):1-5. PubMed ID: 15940843
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
    Lyman GH; Cosler LE; Kuderer NM; Hornberger J
    Cancer; 2007 Mar; 109(6):1011-8. PubMed ID: 17311307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic DNA signature for T1T2 node-negative breast cancer patients.
    Gravier E; Pierron G; Vincent-Salomon A; Gruel N; Raynal V; Savignoni A; De Rycke Y; Pierga JY; Lucchesi C; Reyal F; Fourquet A; Roman-Roman S; Radvanyi F; Sastre-Garau X; Asselain B; Delattre O
    Genes Chromosomes Cancer; 2010 Dec; 49(12):1125-34. PubMed ID: 20842727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A decision analysis of the effect of avoiding axillary lymph node dissection in low risk women with invasive breast carcinoma.
    Jackson JS; Olivotto IA; Wai M D E; Grau C; Mates D; Ragaz J
    Cancer; 2000 Apr; 88(8):1852-62. PubMed ID: 10760762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular markers of breast axillary lymph node metastasis.
    Cavalli LR
    Expert Rev Mol Diagn; 2009 Jul; 9(5):441-54. PubMed ID: 19580429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple gene signatures aim to qualify risk in breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2005 Mar; 97(5):332. PubMed ID: 15741566
    [No Abstract]   [Full Text] [Related]  

  • 16. Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?
    Lamond NW; Skedgel C; Younis T
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):243-50. PubMed ID: 23570435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features and prognostic factors of small breast cancer with multiple axillary lymph node metastasis].
    Liao YQ; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):615-8. PubMed ID: 18210884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of GeneSearch breast lymph node assay to detect sentinel node metastases in early stage breast cancer.
    Technol Eval Cent Assess Program Exec Summ; 2008 Feb; 22(8):1-6. PubMed ID: 18411499
    [No Abstract]   [Full Text] [Related]  

  • 20. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.